Bio Plus Statistics
Total Valuation
Bio Plus has a market cap or net worth of KRW 382.88 billion. The enterprise value is 441.72 billion.
| Market Cap | 382.88B | 
| Enterprise Value | 441.72B | 
Important Dates
The next estimated earnings date is Friday, November 14, 2025.
| Earnings Date | Nov 14, 2025 | 
| Ex-Dividend Date | Dec 27, 2024 | 
Share Statistics
Bio Plus has 60.01 million shares outstanding. The number of shares has increased by 5.97% in one year.
| Current Share Class | 60.01M | 
| Shares Outstanding | 60.01M | 
| Shares Change (YoY) | +5.97% | 
| Shares Change (QoQ) | +1.48% | 
| Owned by Insiders (%) | 32.08% | 
| Owned by Institutions (%) | 6.05% | 
| Float | 40.43M | 
Valuation Ratios
The trailing PE ratio is 26.45.
| PE Ratio | 26.45 | 
| Forward PE | n/a | 
| PS Ratio | 4.29 | 
| PB Ratio | 2.23 | 
| P/TBV Ratio | 2.62 | 
| P/FCF Ratio | n/a | 
| P/OCF Ratio | 17.65 | 
| PEG Ratio | n/a | 
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.14, with an EV/FCF ratio of -7.28.
| EV / Earnings | 27.25 | 
| EV / Sales | 4.95 | 
| EV / EBITDA | 14.14 | 
| EV / EBIT | 16.07 | 
| EV / FCF | -7.28 | 
Financial Position
The company has a current ratio of 0.54, with a Debt / Equity ratio of 0.34.
| Current Ratio | 0.54 | 
| Quick Ratio | 0.34 | 
| Debt / Equity | 0.34 | 
| Debt / EBITDA | 1.84 | 
| Debt / FCF | -0.95 | 
| Interest Coverage | 90.96 | 
Financial Efficiency
Return on equity (ROE) is 12.84% and return on invested capital (ROIC) is 9.03%.
| Return on Equity (ROE) | 12.84% | 
| Return on Assets (ROA) | 7.71% | 
| Return on Invested Capital (ROIC) | 9.03% | 
| Return on Capital Employed (ROCE) | 15.80% | 
| Revenue Per Employee | 713.30M | 
| Profits Per Employee | 129.67M | 
| Employee Count | 125 | 
| Asset Turnover | 0.40 | 
| Inventory Turnover | 2.93 | 
Taxes
| Income Tax | -1.51B | 
| Effective Tax Rate | n/a | 
Stock Price Statistics
The stock price has increased by +17.91% in the last 52 weeks. The beta is 0.56, so Bio Plus's price volatility has been lower than the market average.
| Beta (5Y) | 0.56 | 
| 52-Week Price Change | +17.91% | 
| 50-Day Moving Average | 6,381.80 | 
| 200-Day Moving Average | 6,980.35 | 
| Relative Strength Index (RSI) | 45.40 | 
| Average Volume (20 Days) | 448,485 | 
Short Selling Information
| Short Interest | n/a | 
| Short Previous Month | n/a | 
| Short % of Shares Out | n/a | 
| Short % of Float | n/a | 
| Short Ratio (days to cover) | n/a | 
Income Statement
In the last 12 months, Bio Plus had revenue of KRW 89.16 billion and earned 16.21 billion in profits. Earnings per share was 241.25.
| Revenue | 89.16B | 
| Gross Profit | 58.98B | 
| Operating Income | 27.70B | 
| Pretax Income | 19.07B | 
| Net Income | 16.21B | 
| EBITDA | 31.45B | 
| EBIT | 27.70B | 
| Earnings Per Share (EPS) | 241.25 | 
Balance Sheet
The company has 15.96 billion in cash and 57.81 billion in debt, giving a net cash position of -41.85 billion or -697.34 per share.
| Cash & Cash Equivalents | 15.96B | 
| Total Debt | 57.81B | 
| Net Cash | -41.85B | 
| Net Cash Per Share | -697.34 | 
| Equity (Book Value) | 171.36B | 
| Book Value Per Share | 2,622.08 | 
| Working Capital | -43.82B | 
Cash Flow
In the last 12 months, operating cash flow was 21.69 billion and capital expenditures -82.35 billion, giving a free cash flow of -60.66 billion.
| Operating Cash Flow | 21.69B | 
| Capital Expenditures | -82.35B | 
| Free Cash Flow | -60.66B | 
| FCF Per Share | -1,010.88 | 
Margins
Gross margin is 66.15%, with operating and profit margins of 31.07% and 18.18%.
| Gross Margin | 66.15% | 
| Operating Margin | 31.07% | 
| Pretax Margin | 21.39% | 
| Profit Margin | 18.18% | 
| EBITDA Margin | 35.27% | 
| EBIT Margin | 31.07% | 
| FCF Margin | n/a | 
Dividends & Yields
This stock pays an annual dividend of 50.00, which amounts to a dividend yield of 0.78%.
| Dividend Per Share | 50.00 | 
| Dividend Yield | 0.78% | 
| Dividend Growth (YoY) | -28.57% | 
| Years of Dividend Growth | n/a | 
| Payout Ratio | 17.99% | 
| Buyback Yield | -5.97% | 
| Shareholder Yield | -5.19% | 
| Earnings Yield | 4.23% | 
| FCF Yield | -15.84% | 
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | 
Stock Splits
The last stock split was on November 23, 2022. It was a forward split with a ratio of 4.
| Last Split Date | Nov 23, 2022 | 
| Split Type | Forward | 
| Split Ratio | 4 | 
Scores
Bio Plus has an Altman Z-Score of 3.16 and a Piotroski F-Score of 7.
| Altman Z-Score | 3.16 | 
| Piotroski F-Score | 7 |